Ziyi Chen

I am a biotechnology-focused financial analyst who synthesizes clinical and market data into actionable investment insights for institutional clients. My work spans equity research, therapeutics analytics, and institutional fundraising, with a strong emphasis on oncology and immunology.

At Oppenheimer I built DCF and SOTP valuation models, drafted initiation reports, and presented findings to institutional investors. I partner with senior analysts in client-facing briefings and integrate scientific evidence with market analytics to generate investment recommendations.

In quantitative strategy roles I designed frameworks to model therapeutic asset value, forecasted investor returns across funding and trial outcomes, and conducted competitive benchmarking to identify high return-to-risk indications. I also translate complex scientific data into concise business recommendations for portfolio reviews.

As a researcher I performed computational analyses of tumor microenvironments and designed models simulating tumor–immune interactions, bridging translational science with commercial relevance. I aim to join teams where I can continue marrying technical science with rigorous financial analysis to support data-driven investment decisions.